Why the study?
Despite widespread primary percutaneous intervention and modern antithrombotic therapy, STEMI remains a leading cause of death, and certain high-risk patients present diagnostic and therapeutic challenges.
This review provides an analysis of state-of-the-art treatments for high-risk STEMI patients, including those with cardiogenic shock, cardiac arrest, and mechanical complications.
Answers are grounded in this paper and cite their sources.
May inform high-risk STEMI care; leaves open optimal strategies pending prospective trials.
Despite the widespread adoption of primary percutaneous intervention and modern antithrombotic therapy, ST-segment elevation myocardial infarction (STEMI) remains the leading cause of death in the United States and remains one of the most important causes of morbidity and mortality worldwide. Certain high-risk patients present a challenge for diagnosis and treatment. The widespread adoption of primary percutaneous intervention in addition to modern antithrombotic therapy has resulted in substantial improvement in the short- and long-term prognosis following STEMI. In this review, we aim to provide a brief analysis of the state-of-the-art treatment for patients presenting with STEMI, focusing on cardiogenic shock, current treatment and controversies, cardiac arrest, and diagnosis and treatment of mechanical complications, as well as multivessel and left main-related STEMI.
No takes yet. Share an insight, caveat, or question.
Omer et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: